Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100589 · ClinicalTrials.gov registry record · NA
Effect of PeakATP on Mood, Reaction Time and Cognition
A NA study of Cognitive Change and Mood, sponsored by University of Central Florida.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05100589: Completed NA study of Cognitive Change and Mood, sponsored by University of Central Florida.
NCT05100589 is a NA study of Cognitive Change and Mood that has completed, run by University of Central Florida. The registered enrollment target is 35 participants, below the 179-participant average among 44 other Cognitive Change trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05100589, a NA study of Cognitive Change and Mood, has completed, sponsored by University of Central Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Oral ATP disodium (adenosine 5'- triphosphate disodium) is a commercially available product available alone and as a constituent in a number of sports supplements that is purported to maintain ATP levels and improve performance during high-intensity exercise. Acute deficits in cognitive performance have also been reported in both young adults and children following high-intensity exercise; however, the effects of supplemental ATP on cognitive performance has not been studied. Goals: 1. To investigate the effect of ATP supplementation versus. placebo on mood, reaction time and cognitive performance before and after an acute bout of fatiguing exercise. 2. To investigate the effect of ATP supplementation versus. placebo on anaerobic performance.
Primary Outcome
Assessed via administration of the POMS Questionnaire. 58 words or phrases are presented in a Likert format questionnaire reflecting how the subject feels at the time of completing the questionnaire. Scores range from 0 (Not at all) to 4 (Extremely). Tension, depression, anger, vigor, fatigue, confusion and total mood disturbance (TMD) will be measured.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT PeakATP
Study Locations (1)
Florida
- Kinesiology Research Labs - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-04-19 |
| Phase | NA |
What the finished NCT05100589 record still lists
NCT05100589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 179-participant average among 44 other Cognitive Change trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Cognitive Change appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05100589 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05100589 about?
NCT05100589 is a clinical study titled "Effect of PeakATP on Mood, Reaction Time and Cognition". Oral ATP disodium (adenosine 5'- triphosphate disodium) is a commercially available product available alone and as a constituent in a number of sports supplements that is purported to maintain ATP levels and improve performance during high-intensity exercise. Acute deficits in cognitive performance ...
What is the current status of trial NCT05100589?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2021-10-06. Estimated completion is 2022-04-19.
What conditions does trial NCT05100589 study?
This clinical trial studies the following conditions: Cognitive Change, Mood.
What interventions are being tested in trial NCT05100589?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), PeakATP (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05100589?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05100589 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Change
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05100589's enrollment target sits among peer trials
35 37th of 44 higher than 8 of 44 other Cognitive Change trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Change trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognition After OSA Treatment Among Native American People (CATNAP)
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
-
Moderators and Mediators of Perceptual Learning
RECRUITING · NA
-
Amplitude Titration to Improve ECT Clinical Outcomes
RECRUITING · NA
-
The Role of the Time of Day in the Effects of Exercise on Memory in Heathy Young Adults
RECRUITING · NA
-
Remote Evaluation of MIND Diet
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI